Citations

Showing 10 of 108083 citations.

Laryngeal Cysts in Adults: Simplifying Classification and Management
Heyes, Richard , Lott, David G.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 1, 2017 | Volume: 157 | Issue: 6 | Pages: 928-939

10.1177/0194599817715613 | PMID 28695764 Get It

Objective Laryngeal cysts may occur at any mucosa‐lined location within the larynx and account for 5% to 10% of nonmalignant laryngeal lesions. A number of proposed classifications for laryngeal cysts exist; however, no previously published classification aims to guide management. This review analyzes contemporary laryngeal cyst management and proposes a framework for the terminology and management of cystic lesions in the larynx. Data Sources PubMed/Medline. Review Methods A primary literature search of the entire Medline database was performed for all titles of publications pertaining to laryngeal cysts and reviewed for relevance. Full manuscripts were reviewed per the relevance of their titles and abstracts, and selection into this review was according to their clinical and scientific relevance. Conclusion Laryngeal cysts have been associated with rapid‐onset epiglottitis, dyspnea, stridor, and death; therefore, they should not be considered of little significance. Symptoms are varied and nonspecific. Laryngoscopy is the primary initial diagnostic tool. Cross‐sectional imaging may be required, and future use of endolaryngeal ultrasound and optical coherence tomography may revolutionize practice. Where possible, cysts should be completely excised, and there is growing evidence that a transoral approach is superior to transcervical excision for nearly all cysts. Histology provides definitive diagnosis, and oncocytic cysts require close follow‐up. Implications for Practice A new classification system is proposed that increases clarity in terminology, with the aim of better preparing surgeons and authors for future advances in the understanding and management of laryngeal cysts.
Cardiac MR elastography using reduced‐FOV, single‐shot, spin‐echo EPI
Sui, Yi , Arunachalam, Shivaram P. , Arani, Arvin , Trzasko, Joshua D. , Young, Phillip M. , Glockner, James F., Glaser, Kevin J. , Lake, David S. , McGee, Kiaran P. , Rossman, Phillip J. , Araoz, Philip A. , Arunachalam, S P , Arani, Arvin , Manduca, Armando , Ehman, Richard L. , Sui, Yi

Mayo Clinic

Magnetic Resonance in Medicine | December 1, 2017 | Volume: 80 | Issue: 1 | Pages: 231-238

10.1002/mrm.27029 | PMID 29194738 Get It

PurposeTo implement a reduced field of view (rFOV) technique for cardiac MR elastography (MRE) and to demonstrate the improvement in image quality of both magnitude images and post‐processed MRE stiffness maps compared to the conventional full field of view (full‐FOV) acquisition.MethodsWith Institutional Review Board approval, 17 healthy volunteers underwent both full‐FOV and rFOV cardiac MRE scans using 140‐Hz vibrations. Two cardiac radiologists blindly compared the magnitude images and stiffness maps and graded the images based on several image quality attributes using a 5‐point ordinal scale. Fisher's combined probability test was performed to assess the overall evaluation. The octahedral shear strain‐based signal‐to‐noise ratio (OSS‐SNR) and median stiffness over the left ventricular myocardium were also compared.ResultsOne volunteer was excluded because of an inconsistent imaging resolution during the exam. In the remaining 16 volunteers (9 males, 7 females), the rFOV scans outperformed the full‐FOV scans in terms of subjective image quality and ghosting artifacts in the magnitude images and stiffness maps, as well as the overall preference. The quantitative measurements showed that rFOV had significantly higher OSS‐SNR (median: 1.4 [95% confidence interval (CI): 1.2–1.5] vs. 2.1 [95% CI: 1.8–2.4]), P < 0.05) compared to full‐FOV. Although no significant change was found in the median myocardial stiffness between the 2 scans, we observed a decrease in the stiffness variation within the myocardium from 2.1 kPa (95% CI: [1.9, 2.3]) to 1.9 kPa (95% CI: [1.7, 2.0]) for full‐FOV and rFOV, respectively (P < 0.05) in a subgroup of 7 subjects with ghosting present in the myocardium.ConclusionThis pilot volunteer study demonstrated that rFOV cardiac MRE has the capability to reduce ghosting and to improve image quality in both MRE magnitude images and stiffness maps. Magn Reson Med 80:231–238, 2018. © 2017 The Authors Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection
Greenblatt, David J. , Harmatz, Jerold S., Nicholson, Wayne T. , Rubino, Christopher M. , Chow, Christina R. , Patel, Maulik R

Mayo Clinic

The Journal of Clinical Pharmacology | November 30, 2017 | Volume: 58 | Issue: 4 | Pages: 533-540

10.1002/jcph.1040 | PMID 29194698 Get It

AbstractPharmacokinetics and antithrombotic effects of the Factor Xa inhibitor rivaroxaban were studied in subjects with mild renal insufficiency concurrently taking the P‐glycoprotein and moderate CYP3A inhibitor verapamil, a drug commonly administered to patients with hypertension, ischemic heart disease, or atrial fibrillation. Age‐matched controls with normal renal function were studied concurrently. Subjects’ overall mean age was 59 years. Mean creatinine clearance values in the 2 groups were 105 and 71 mL/min. After single 20‐mg oral doses, rivaroxaban area under the curve (AUC) was increased by a factor of 1.11 (ratio of geometric means [RGM]) in mild renal insufficiency compared to controls. Verapamil coadministration independently increased AUC to the same extent in both the mild renal insufficiency and control groups (RGM, 1.39 and 1.43). Concurrent mild renal insufficiency and verapamil produced additive inhibition compared to controls without verapamil (RGM, 1.58). Prothrombin time (PT) prolongation and Factor Xa inhibition tracked plasma rivaroxaban, and were enhanced by verapamil. Concentration–response relationships for PT (linear) and Factor Xa inhibition (hyperbolic) were unaffected by renal function or verapamil. The absolute and relative increases in rivaroxaban AUC caused by verapamil in mild renal insufficiency subjects are potentially associated with an increased bleeding risk. Modification of recommended dosage may be required in this combination of circumstances to reduce risk to patients.
Polycythemia vera and essential thrombocythemia: algorithmic approach
Tefferi, Ayalew , Vannucchi, Alessandro M. , Guglielmelli, Paola

Mayo Clinic

Current Opinion in Hematology | November 30, 2017 | Volume: 25 | Issue: 2 | Pages: 112-119

10.1097/moh.0000000000000402 | PMID 29194068 Get It

Purpose of review To describe an algorithm-based approach, whenever available, to the diagnosis, the risk stratification criteria informing therapy and the current management of polycythemia vera and essential thrombocythemia. Recent findings Description of recurrent genetic abnormalities in driver genes, including Janus Kinase 2 (JAK2), myeloproliferative leukemia and calreticulin, a better appreciation of the key diagnostic role of bone marrow features, results of large epidemiologic studies and a few but landmark controlled clinical trials produced in the last decade, all resulted in a reappraisal of the approach to polycythemia vera and essential thrombocythemia. Summary The revised 2017 WHO classification of polycythemia vera and essential thrombocythemia allows early diagnosis and accurate distinction from other chronic myeloproliferative neoplasms, particulary prefibrotic myelofibrosis. The prognostic value of selected mutations is being appreciated and JAK2V617F mutation is currently incorporated as risk variable in prognostic system for essential thrombocythemia. Risk-adjusted stratification is used to select therapeutic approaches that include target agents. However, there is not yet a curative approach to these hematologic neoplasms, and although their management has much improved in the last decades, the associated morbidity and mortality remains significant and may be worsened by toxicities of therapeutic agents. Therefore, several clinically relevant endpoints remain unmet.
Hearing Outcomes After Stereotactic Radiosurgery for Jugular Paraganglioma
Patel, Neil , Link, Michael J. , Driscoll, Colin L. W., Pollock, Bruce E. , Lohse, Christine M. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | November 30, 2017 | Volume: 39 | Issue: 1 | Pages: 99-105

10.1097/mao.0000000000001636 | PMID 29194225 Get It

Objective: To describe audiometric outcomes following stereotactic radiosurgery (SRS) for jugular paraganglioma (JP). Study Design: Retrospective review. Setting: Tertiary referral center. Patients: Patients with pretreatment serviceable hearing (American Academy of Otolaryngology—Head and Neck Surgery [AAO-HNS] Class A or B) and serial post-SRS audiometric follow-up who underwent Gamma Knife SRS for JP between 1990 and 2017. Intervention(s): Gamma Knife SRS. Main Outcome Measures: Progression to nonserviceable hearing; correlation between baseline hearing and treatment parameters with audiometric outcomes. Results: Of 85 patients with JP who underwent SRS during the study period, 35 (66% female, median age 53) had pretreatment serviceable hearing and serial post-treatment audiometry available for review. Median tumor volume at the time of treatment was 7,080 mm3, median cochlear point dose was 5.8 Gy (interquartile range [IQR] 4.1 to 7.3 Gy), and median marginal and maximum tumor doses were 16 and 32 Gy, respectively. After a median follow-up of 37 months (IQR 16 to 77 mo), the median change in pure-tone average and speech discrimination score in the treated ear was −1.2 dB HL/yr (IQR −4.5 to 0.3) and 0%/yr (IQR 0–3.5%), compared with 0.07 dB HL/yr (IQR −0.03 to 0.12) and 0 %/yr (IQR 0 to 0%) in the contralateral untreated ear. Seven patients developed nonserviceable hearing (AAO-HNS Class C or D) at a median of 13.2 months following SRS (IQR 4.8 to 24 mo). Among those who maintained serviceable hearing, median audiometric follow-up was 42 months (IQR 18 to 77 mo). The Kaplan–Meier estimated rates of serviceable hearing at 1, 3, and 5 years following SRS were 91%, 80%, and 80%, respectively. Sixty percent of patients with pulsatile tinnitus who underwent SRS experienced varying levels of symptomatic improvement following treatment. Conclusion: The short- and intermediate-term risk of progression to nonserviceable hearing following SRS for JP is low. Data regarding the impact of cochlear dose from the vestibular schwannoma literature should not be freely applied to JP, since the impact of SRS parameters on hearing preservation seems to be less significant.
Pregnancy history, coronary artery calcification and bone mineral density in menopausal women
Beckman, John , Camp, Jon J. , Lahr, Brian D. , Bailey, Kent R. , Kearns, Ann E. , Jayachandran, Muthuvel , Miller, Virginia M. , Holmes, David R. , Garovic, Vesna D.

Mayo Clinic

Climacteric | November 30, 2017 | Volume: 21 | Issue: 1 | Pages: 53-59

10.1080/13697137.2017.1406910 | PMID 29189095 Get It

Faculty Opinions recommendation of Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging.
Wu, Long‐Jun , Eyo, Ukpong B

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 30, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.729490031.793539465 Get It

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Norquist, Barbara M. , Brady, Mark F. , Harrell, Maria I., Lee, Ming K. , Bernards, Sarah S., Casadei, Silvia , Burger, Robert A. , Tewari, Krishnansu S. , Mannel, Robert S., Bailey, Cheryl L., Rubin, Stephen C. , Soper, John T. , Lankes, Heather A. , Ramirez, Nilsa C. , King, Mary‐Claire , Birrer, Michael J. , Swisher, Elizabeth M. , Glaser, Gretchen , Swisher, Elizabeth M , Walsh, Tom D. , Gülsüner, Süleyman , Backes, Floor , Norquist, Barbara

Mayo Clinic

Clinical Cancer Research | November 30, 2017 | Volume: 24 | Issue: 4 | Pages: 777-783

10.1158/1078-0432.ccr-17-1327 | PMID 29191972 Get It

Abstract Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab. Experimental Design: We sequenced DNA from blood and/or neoplasm from 1,195 women enrolled in GOG-0218, a randomized phase III trial in advanced ovarian carcinoma of bevacizumab added to carboplatin and paclitaxel. Defects in HRR were defined as damaging mutations in 16 genes. Proportional hazards models were used to estimate relative hazards for progression-free survival (PFS) and overall survival (OS). Results: Of 1,195 women with ovarian carcinoma, HRR mutations were identified in 307 (25.7%). Adjusted hazards for progression and death compared with those without mutations were lower for women with non-BRCA HRR mutations [HR = 0.73; 95% confidence interval (CI), 0.57–0.94; P = 0.01 for PFS; HR = 0.67; 95% CI, 0.50–0.90; P = 0.007 for OS] and BRCA1 mutations (HR = 0.80; 95% CI, 0.66–0.97; P = 0.02 for PFS; HR = 0.74; 95% CI, 0.59–0.94; P = 0.01 for OS) and were lowest for BRCA2 mutations (HR = 0.52; 95% CI, 0.40–0.67; P &lt; 0.0001 for PFS; HR = 0.36; 95% CI, 0.25–0.53; P &lt; 0.0001 for OS). A test of interaction showed no difference in the effect of bevacizumab on PFS between cases with and without mutations. Conclusions: HRR mutations, including non-BRCA genes, significantly prolong PFS and OS in ovarian carcinoma and should be stratified for in clinical trials. The benefit of adding bevacizumab was not significantly modified by mutation status. Clin Cancer Res; 24(4); 777–83. ©2017 AACR.
Faculty Opinions recommendation of A new fate mapping system reveals context-dependent random or clonal expansion of microglia.
Wu, Long‐Jun , Eyo, Ukpong B

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 30, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727513664.793539464 Get It

International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)
O’Mahony, Constantinos , Jichi, Fatima, Ommen, Steve R. , Christiaans, Imke , Arbustini, Eloisa , García‐Pavía, Pablo , Olivotto, Iacopo , Kitaoka, Hiroaki , Gotsman, Israel , Carr‐White, Gerald, Mogensen, Jens , Antoniades, Loizos , Tang, Hak Chiaw , Geske, Jeffrey B. , Siontis, Konstantinos C. , Mahmoud, Karim D. , Vermeer, Alexa M.C. , Wilde, Arthur A.M. , Favalli, Valentina , Guttmann, Oliver , Gallego‐Delgado, María , Domínguez, Fernándo , Tanini, Ilaria , Kubo, Toru , Keren, Andre , Bueser, Teofila , Waters, Sarah, Issa, Issa Farah , Malcolmson, James , Burns, Tom, Sekhri, Neha, Hoeger, Christopher W. , Omar, Rumana , Elliott, Perry , Olivotto, Iacopo , Garcia-Pavia, Pablo , Geske, Jeffrey B , Cecchi, Franco , Mohiddin, Saidi , Maurer, Matthew J. , Dominguez, Fernando

Mayo Clinic

Circulation | November 30, 2017 | Volume: 137 | Issue: 10 | Pages: 1015-1023

10.1161/circulationaha.117.030437 | PMID 29191938 Get It

Background: Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter defibrillator is challenging. In 2014, the European Society of Cardiology proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) that estimates the 5-year risk of SCD. The aim was to externally validate the 2014 European Society of Cardiology recommendations in a geographically diverse cohort of patients recruited from the United States, Europe, the Middle East, and Asia. Methods: This was an observational, retrospective, longitudinal cohort study. Results: The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end point within 5 years of follow-up (5-year incidence, 2.4% [95% confidence interval {CI}, 1.9–3.0]). The validation study revealed a calibration slope of 1.02 (95% CI, 0.93–1.12), C-index of 0.70 (95% CI, 0.68–0.72), and D-statistic of 1.17 (95% CI, 1.05–1.29). In a complete case analysis (n= 2147; 44 SCD end points at 5 years), patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI, 0.8–2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI, 5.96–13.1) at 5 years. For every 13 (297/23) implantable cardioverter defibrillator implantations in patients with an estimated 5-year SCD risk ≥6%, 1 patient can potentially be saved from SCD. Conclusions: This study confirms that the HCM Risk-SCD model provides accurate prognostic information that can be used to target implantable cardioverter defibrillator therapy in patients at the highest risk of SCD.